Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSinclair Pharma Regulatory News (SPH)

  • There is currently no data for SPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 Oct 2018 10:35

RNS Number : 6135E
Sinclair Pharma PLC
19 October 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

SINCLAIR PHARMA PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

TOSCAFUND ASSET MANAGEMENT LLP

City and country of registered office (if applicable)

LONDON, ENGLAND

4. Full name of shareholder(s) (if different from 3.)v

Name

TOSCA MID CAP

TOSCA OPPORTUNITY

THE PEGASUS FUND LIMITED

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

16/10/2018

6. Date on which issuer notified (DD/MM/YYYY):

18/10/2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

11.24%

N/A

11.24%

503,768,952

Position of previous notification (if

applicable)

29.0%

N/A

29.0%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB0033856740

0

56,613,603

0

11.24%

SUBTOTAL 8. A

56,613,603

11.24%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

N/A

N/A

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

N/A

N/A

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

None

 

Place of completion

LONDON, ENGLAND

Date of completion

18/10/2018

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLMLBLTMBJBMIP
Date   Source Headline
12th Jul 20185:06 pmRNSForm 8.3 Sinclair Pharma plc Replacement
12th Jul 20185:05 pmRNSForm 8.3 Sinclair Pharma plc Replacement
12th Jul 201812:17 pmRNSForm 8.3 - Sinclair Pharma plc
12th Jul 201812:17 pmRNSForm 8.3 - Sinclair Pharma PLC
12th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
11th Jul 20182:20 pmRNSForm 8.3 - Sinclair Pharma Plc
11th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
11th Jul 20189:11 amRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc - Restated
11th Jul 20188:19 amRNSForm 8.5 (EPT/RI) - Sinclar Pharma Plc
10th Jul 20183:01 pmRNSForm 8.3 - Sinclair Pharma plc
10th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
10th Jul 201810:32 amRNSForm 8.5 (EPT/RI) - Sinclar Pharma Plc
9th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
6th Jul 20183:42 pmBUSForm 8.3 - SINCLAIR PHARMA PLC
6th Jul 20183:37 pmRNSForm 8.3 - Sinclair Pharma plc
6th Jul 20182:15 pmRNSForm 8.3 - [Sinclair Pharma plc]
6th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
6th Jul 201810:30 amRNSForm 8.3 - Sinclair Pharma Plc
5th Jul 20186:03 pmRNSStatement re Possible Offer
5th Jul 20181:32 pmRNSStatement re Possible Offer
5th Jul 20187:00 amRNSTrading Update
13th Jun 201811:06 amRNSResult of AGM
13th Jun 20187:00 amRNSAGM Statement
23rd May 20188:00 amRNSSilhouette Instalift wins NewBeauty Magazine Award
18th May 20188:00 amRNSPublication of Annual Report and Accounts
30th Apr 20187:01 amRNSFinal Results
30th Apr 20187:00 amRNSSinclair secures Euro23 million debt facility
26th Mar 20187:00 amRNSUpdate on US distribution of Silhouette Instalift
6th Mar 20187:00 amRNSHolding(s) in Company
2nd Mar 20187:00 amRNSHolding(s) in Company
1st Mar 201810:06 amRNSHolding(s) in Company
22nd Feb 20187:01 amRNSSinclair announces $5m investment by EW Healthcare
22nd Feb 20187:00 amRNSSinclair and ThermiGen terminate agreement
17th Jan 20187:00 amRNSDirector/PDMR Shareholding
16th Jan 20182:15 pmRNSDirector/PDMR Shareholding
16th Jan 20187:00 amRNSEllansé® Approved for Sale in Brazil
15th Jan 20187:00 amRNSTrading Statement
19th Oct 20172:25 pmRNSNew CE mark granted for Silhouette Soft
2nd Oct 20177:15 amRNSHardman Research: Demand growing in target markets
19th Sep 20177:00 amRNSInterim Results
12th Jul 20177:47 amRNSHolding(s) in Company
12th Jul 20177:15 amRNSHardman Research: Promising start in the US
11th Jul 20177:00 amRNSTrading Update for the 6 months to 30 June 2017
5th Jul 20177:00 amRNSHolding(s) in Company
19th Jun 20177:00 amRNSAcquisition
14th Jun 20177:00 amRNSHolding(s) in Company
24th May 20177:00 amRNSHolding(s) in Company
26th Apr 201710:50 amRNSResult of AGM
30th Mar 20174:55 pmRNSAnnual Financial Report
30th Mar 20177:00 amRNSAdditional listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.